A Glance on Nanovaccine: A Potential Approach for Disease Prevention
- PMID: 37861010
- DOI: 10.2174/0113892010254221231006100659
A Glance on Nanovaccine: A Potential Approach for Disease Prevention
Abstract
There are several vaccines available for preventing various bacterial and viral infections, but still, there are many challenges that require the development of noninvasive, more efficient, and active vaccines. The advancement in biotechnological tools has provided safer antigens, such as nucleic acids, proteins etc., but due to their lower immunogenic property, adjuvants of stronger immune response are required. Nanovaccines are effective vaccines when compared with conventional vaccines as they can induce both Humoral and cell-mediated immune responses and also provide longer immunogenic memory. The nanocarriers used in vaccines act as adjuvant. They provide site-specific delivery of antigens and can be used in conjugation with immunostimulatory molecules for enhancing adjuvant therapy. The nanovaccines avoid degrading cell pathways and provide effective absorption into blood vessels. The higher potential of nanovaccines to treat various diseases, such as acquired immuno deficiency syndrome, cancer, tuberculosis, malaria and many others, along with their immunological mechanisms and different types, have been discussed in the review.
Keywords: Vaccine; cell-mediated.; humoral; immune response; infectious diseases; nanovaccine.
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
Similar articles
-
Nanovaccine: A novel approach in immunization.J Cell Physiol. 2019 Aug;234(8):12530-12536. doi: 10.1002/jcp.28120. Epub 2019 Jan 11. J Cell Physiol. 2019. PMID: 30633361 Review.
-
Advancements in prophylactic and therapeutic nanovaccines.Acta Biomater. 2020 May;108:1-21. doi: 10.1016/j.actbio.2020.03.020. Epub 2020 Apr 5. Acta Biomater. 2020. PMID: 32268235 Free PMC article. Review.
-
Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections.Acta Biomater. 2023 Mar 1;158:525-534. doi: 10.1016/j.actbio.2022.12.042. Epub 2022 Dec 23. Acta Biomater. 2023. PMID: 36572250
-
Self-adjuvanting polymeric nanovaccines enhance IFN production and cytotoxic T cell response.J Control Release. 2024 May;369:556-572. doi: 10.1016/j.jconrel.2024.04.005. Epub 2024 Apr 10. J Control Release. 2024. PMID: 38580136
-
Self-adjuvanting cancer nanovaccines.J Nanobiotechnology. 2022 Jul 26;20(1):345. doi: 10.1186/s12951-022-01545-z. J Nanobiotechnology. 2022. PMID: 35883176 Free PMC article. Review.
Cited by
-
Biomimetic nanovaccines in cancer therapy: mechanisms, efficacy, and clinical translation.Mater Today Bio. 2025 Jul 18;34:102116. doi: 10.1016/j.mtbio.2025.102116. eCollection 2025 Oct. Mater Today Bio. 2025. PMID: 40791791 Free PMC article. Review.
References
-
- Sekhon B.; Sekhon B.; Saluja V.; Nanovaccines-An overview. Inter J Pharma Frontier Res 2011,1,101-109
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical